Association of KLK5 overexpression with invasiveness of urinary bladder carcinoma cells

Cancer Science

Volumn 98, Issue 7, 2007, Pages 1078-1086

  Shinoda, Yasuo ^a,b,c   Kozaki, Ken Ichi ^a,b   Imoto, Issei ^a,b   Obara, Wataru ^f   Tsuda, Hitoshi ^a,b,d   Mizutani, Yoichi ^c   Shuin, Taro ^e   Fujioka, Tomoaki ^f   Miki, Tsuneharu ^c   Inazawa, Johji ^a,b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^e KOCHI MEDICAL SCHOOL   (Japan)

^f IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; KALLIKREIN; KALLIKREIN 5; KALLIKREIN 6; KALLIKREIN 9; METHOTREXATE; NEUROPSIN; SERINE PROTEINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VINBLASTINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER INVASION; CANCER RECURRENCE; CHROMOSOME 19Q; CHROMOSOME MAP; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MULTIPLE CYCLE TREATMENT; NUMERICAL CHROMOSOME ABERRATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERFICIAL CANCER;

CARCINOMA; CELL DIVISION; CELL LINE, TUMOR; GENE AMPLIFICATION; HUMANS; KALLIKREINS; NEOPLASM INVASIVENESS; NUCLEIC ACID HYBRIDIZATION; URINARY BLADDER NEOPLASMS;

EID: 34249866906     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00495.x     Document Type: Article

References (34)

1. Donat SM. Evaluation and follow-up strategies for superficial bladder cancer. Urol Clin North Am 2003; 30: 765-76.
2. von der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23: 4602-8.
3. Veltman JA, Fridlyand J, Pejavar S et al. Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res 2003; 63: 2872-80.
4. Blaveri E, Brewer JL, Roydasgupta R et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res 2005; 11: 7012-22.
5. Inazawa J, Inoue J, Imoto I. Comparative genomic hybridization (CGH)-arrays pave the way for identification of novel cancer-related genes. Cancer Sci 2004; 95: 559-63.
6. Sonoda I, Imoto I, Inoue J et al. Frequent silencing of low density lipoprotein receptor-related protein 1B (LRP1B) expression by genetic and epigenetic mechanisms in esophageal squamous cell carcinoma. Cancer Res 2004; 64: 3741-7.
7. Izumi H, Inoue J, Yokoi S et al. Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers. Hum Mol Genet 2005; 14: 997-1007.
8. Takada H, Imoto I, Tsuda H et al. ADAM23, a possible tumor suppressor gene, is frequently silenced in gastric cancers by homozygous deletion or aberrant promoter hypermethylation. Oncogene 2005; 24: 8051-60.
9. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 2001; 22: 184-204.
10. Clements J, Hooper J, Dong Y, Harvey T. The expanded human kallikrein (KLK) gene family: Genomic organisation, tissue-specific expression and potential functions. Biol Chem 2001; 382: 5-14.
11. Borgono CA, Michael IP, Diamandis EP. Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2004; 2: 257-80.
12. Michael IP, Sotiropoulou G, Pampalakis G et al. Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J Biol Chem 2005; 280: 14.628-35.
13. Rajapakse S, Ogiwara K, Takano N, Moriyama A, Takahashi T. Biochemical characterization of human kallikrein 8 and its possible involvement in the degradation of extracellular matrix proteins. FEBS Lett 2005; 579: 6879-84.
14. Obiezu CV, Diamandis EP. Human tissue kallikrein gene family: applications in cancer. Cancer Lett 2005; 224: 1-22.
15. Nagahara H, Mimori K, Utsunomiya T et al. Clinicopathologic and biological significance of kallikrein 6 overexpression in human gastric cancer. Clin Cancer Res 2005; 11: 6800-6.
16. Fukuda Y, Kurihara N, Imoto I et al. CD44 is a potential target of amplification within the 11p13 amplicon detected in gastric cancer cell lines. Genes Chromosomes Cancer 2000; 29: 315-24.
17. Harvey TJ, Hooper JD, Myers SA, Stephenson SA, Ashworth LK, Clements JA. Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4. J Biol Chem 2000; 275: 37.397-406.
18. Yousef GM, Scorilas A, Katsaros D et al. Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. J Clin Oncol 2003; 21: 3119-26.
19. Hurst CD, Fiegler H, Carr P, Williams S, Carter NP, Knowles MA. High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization. Oncogene 2004; 23: 2250-63.
20. Baffa R, Gomella LG, Vecchione A et al. Loss of FHIT expression in transitional cell carcinoma of the urinary bladder. Am J Pathol 2000; 156: 419-24.
21. Bringuier PP, Tamimi Y, Schuuring E, Schalken J. Expression of cyclin D1 and EMS1 in bladder tumours: Relationship with chromosome 11q13 amplification. Oncogene 1996; 12: 1747-53.
22. Shimoyama Y, Gotoh M, Terasaki T, Kitajima M, Hirohashi S. Isolation and sequence analysis of human cadherin-6 complementary DNA for the full coding sequence and its expression in human carcinoma cells. Cancer Res 1995; 55: 2206-11.
23. Galang CK, Muller WJ, Foos G, Oshima RG, Hauser CA. Changes in the expression of many Ets family transcription factors and of potential target genes in normal mammary tissue and tumors. J Biol Chem 2004; 279: 11.281-92.
24. Chaib H, Rubin MA, Mucci NR et al. Activated in prostate cancer: A PDZ domain-containing protein highly expressed in human primary prostate tumors. Cancer Res 2001; 61: 2390-4.
25. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909-16.
26. McCormack RT, Rittenhouse HG, Finlay JA et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: A new era. Urology 1995; 45: 729-44.
27. Ni X, Zhang W, Huang KC et al. Characterisation of human kallikrein 6/ protease M expression in ovarian cancer. Br J Cancer 2004; 91: 725-31.
28. Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004; 4: 876-90.
29. Magklara A, Mellati AA, Wasney GA et al. Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity, and regulation by inhibitors. Biochem Biophys Res Commun 2003; 307: 948-55.
30. Moriarty HT, Webster LR. Fragile sites and bladder cancer. Cancer Genet Cytogenet 2003; 140: 89-98.
31. Zaharieva B, Simon R, Ruiz C et al. High-throughput tissue microarray analysis of CMYC amplificationin urinary bladder cancer. Int J Cancer 2005; 117: 952-6.
32. Chapman EJ, Harnden P, Chambers P, Johnston C, Knowles MA. Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype. Clin Cancer Res 2005; 11: 5740-7.
33. Imoto I, Yang ZQ, Pimkhaokham A et al. Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res 2001; 61: 6629-34.
34. Yousef GM, Polymeris ME, Grass L et al. Human kallikrein 5: A potential novel serum biomarker for breast and ovarian cancer. Cancer Res 2003; 63: 3958-65.